Image By: Hilary Marston, MD, MPH, Chief Medical Officer and Kevin Bugin, PhD, Deputy Director of Operations in the Office of New Drugs, Center for Drug […]

On this page Screening and Diagnosing Opioid Use Disorder in Primary Care Settings An estimated 6.1 million people over the age of 12 have an opioid […]

What is Prescribe with Confidence About? Prescribe with Confidence is an educational campaign to help providers recognize and treat opioid use disorder (OUD). Opioid use disorder […]

Action FDA approved Yesafili (aflibercept-jbvf) and Opuviz (aflibercept-yszy) as interchangeable biosimilars to Eylea (aflibercept). Aflibercept products work by inhibiting vascular endothelial growth factor (VEGF) which prevents […]

For Immediate Release: May 17, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Thursday, […]

UPDATE: On May 16, 2024, the FDA announced the final withdrawal of the approval of infigratinib (Truseltiq) for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast […]

A glossary of terms for C3TI’s Compass Knowledge Repository. Area of research: specific domain or subject of innovation Adaptive Trial Design: Flexible trial methodologies allowing modifications based […]

Factor de protección solar (FPS) El valor de FPS indica cuánta protección contra las quemaduras solares proporciona el producto de protección solar. Todos los protectores solares […]

1. What is C3TI Compass?   C3TI Compass is a central location to hold information on the implementation of novel approaches for clinical trials, offering a […]